Madrigal Pharmaceuticals (MDGL) Times Interest Earned (2010 - 2026)
Madrigal Pharmaceuticals (MDGL) posted quarterly Times Interest Earned of -$7.09 for Q2 2026, up 50.42% year-over-year from -$4.71 in Q2 2025, and up 40.2% quarter-over-quarter from -$11.86 in Q1 2026.
Madrigal Pharmaceuticals (MDGL) Times Interest Earned (2010 - 2026) Analysis & Trends
Madrigal Pharmaceuticals (MDGL) has reported Times Interest Earned for 16 consecutive years, with -$7.09 the latest figure, recorded in Q2 2026.
- In Q2 2026, Times Interest Earned rose 50.42% year-over-year to -$7.09; the TTM figure through Jun 2026 stood at -$2.22 (up 99.85% YoY), while the FY2025 annual figure was -$0.51, up 48.11% from the prior year.
- Times Interest Earned improved to -$7.09 in Q2 2026 per MDGL's latest filing, from -$11.86 in the prior quarter.
- Across five years, Times Interest Earned topped out at $6.65 in Q4 2024 and bottomed at -$90.09 in Q2 2022.
- Historically, Times Interest Earned has averaged -$29.26 across 5 years, with a median of -$29.51 in 2023.
- Annual changes were most pronounced in 2024 — Times Interest Earned soared 122.54% — and 2025, when it slumped 107.36%.
- Madrigal Pharmaceuticals' Times Interest Earned stood at -$50.71 in 2022, then soared by 41.81% to -$29.51 in 2023, then jumped by 122.54% to $6.65 in 2024, then slumped by 107.36% to -$0.49 in 2025, then plunged by 1349.36% to -$7.09 in 2026.
- Business Quant data shows MDGL's Times Interest Earned at -$7.09 in Q2 2026, -$11.86 in Q1 2026, and -$0.49 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | Madrigal Pharmaceuticals | 14.79 Bn | 13.95 Bn | - | -7.09 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -7.09 |
| Mar 31, 2026 | -11.86 |
| Dec 31, 2025 | -0.49 |
| Sep 30, 2025 | -15.30 |
| Jun 30, 2025 | -14.46 |
| Mar 31, 2025 | -24.06 |
| Dec 31, 2024 | -19.15 |
| Sep 30, 2024 | -31.61 |
| Jun 30, 2024 | -44.46 |
| Mar 31, 2024 | -39.61 |
| Dec 31, 2023 | -29.51 |
| Sep 30, 2023 | -28.12 |
| Jun 30, 2023 | -29.80 |
| Mar 31, 2023 | -33.53 |
| Dec 31, 2022 | -50.71 |
| Sep 30, 2022 | -53.54 |
| Jun 30, 2022 | -90.09 |
| Dec 31, 2020 | -0.45 |
| Sep 30, 2020 | -3,919.07 |
| Jun 30, 2020 | -25,163.50 |